Creating a new test to predict the risk of uveal melanoma spreading
Development of a Novel Aqueous Humor-Based Multiplex Assay for Uveal Melanoma Metastatic Risk Prediction
This study is looking for a gentler way to check if uveal melanoma, a type of eye cancer, might spread by testing proteins in the eye's fluid instead of using painful needle biopsies, making it easier for patients to get the information they need for their treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Olmeda Biosciences LLC NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-11006367 on NIH RePORTER |
What this research studies
This research focuses on developing a less invasive method to predict the risk of metastasis in patients with uveal melanoma, a type of eye cancer. Instead of relying on painful needle biopsies, the study will analyze proteins found in the aqueous humor, the fluid in the front part of the eye, to identify markers that indicate metastatic risk. By using a safe procedure called AH paracentesis, researchers aim to create a reliable test that can help guide treatment decisions and improve patient monitoring. This innovative approach seeks to enhance patient comfort and reduce healthcare costs while providing accurate prognostic information.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with uveal melanoma who are at risk of developing metastatic disease.
Not a fit: Patients with uveal melanoma who are not at risk of metastasis or those who have already experienced metastasis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more comfortable and accurate way to predict the risk of uveal melanoma spreading, improving patient outcomes.
How similar studies have performed: Similar approaches using proteomic analysis for cancer risk prediction have shown promise, indicating potential success for this novel method.
Where this research is happening
San Diego, United States
- Olmeda Biosciences LLC — San Diego, United States (Active)
Researchers
- Principal investigator: Xu, Liya — Olmeda Biosciences LLC
- Study coordinator: Xu, Liya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.